Sulfonamide carboxamide compounds

CPC - классификация

AA6A61A61KA61K3A61K31A61K31/A61K31/4A61K31/41A61K31/415A61K31/4155A61K31/416A61K31/4164A61K31/44A61K31/443A61K31/4439A61PA61P2A61P29A61P29/A61P29/0A61P29/00CC0C07C07DC07D2C07D23C07D231C07D231/C07D231/1C07D231/18C07D233C07D233/C07D233/8C07D233/84C07D24C07D249C07D249/C07D249/0C07D249/04C07D249/1C07D249/12C07D4C07D40C07D401C07D401/C07D401/0C07D401/06C07D401/1C07D401/12C07D401/14C07D403C07D403/C07D403/0C07D403/06C07D405C07D405/C07D405/0C07D405/04C07D405/06C07D405/1C07D405/12C07D405/14C07D41C07D413C07D413/C07D413/0C07D413/06

IPC - классификация

AA6A61A61PA61P2A61P29A61P29/A61P29/0A61P29/00A61P4A61P43A61P43/A61P43/0A61P43/00CC0C07C07DC07D2C07D23C07D231C07D231/C07D231/1C07D231/18C07D233C07D233/C07D233/8C07D233/84C07D24C07D249C07D249/C07D249/0C07D249/04C07D249/1C07D249/12C07D4C07D40C07D401C07D401/C07D401/0C07D401/06C07D401/1C07D401/12C07D401/14C07D403C07D403/C07D403/0C07D403/06C07D405C07D405/C07D405/0C07D405/04C07D405/06C07D405/1C07D405/12C07D405/14C07D41C07D413C07D413/C07D413/0C07D413/06

Цитирование НПИ

Alsante, et al., “Pharmaceutical Impurity Identification: A Case Study Using a Multidisciplinary Approach,” Journal of Pharmaceutical Sciences, 93(9): 2296-2309, (2004).
Balant ed in Wolff et al. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. vol. 1: Principles and Practice. pp. 949-982, 1995.
Baldwin, J Med Chem, 2015, 1691-1710. (Year: 2015).
Baldwin, et al., “Inhibiting the inflammasome: a chemical perspective,” Journal of Medicinal Chemistry, 59(5): 1691-1710, (2016).
Banker et al., Prodrugs, Modern Pharmaceutics, 3rd edition, Revised and Expanded, pp. 451 and 596.
Belikov, et al., “MEDpress-inform,” Pharmaceutical Chemistry, Text Book, 4th Edition, Moscow, 622 pp. 11, 27-29, (2007), Brief statement of relevance.
Belikov, et al., “The interconnection between chemical structure, properties of substances and their effect on the body”, MEDpress-inform, Pharmaceutical Chemistry, Text Book, 4th Edition, Moscow, Chap. 2.6, 27-29, (2007), Brief statement of relevance.
Booth, et al., “A new and efficient approach to the synthesis of 6-amidino-2-oxopurines,” Journal of the Chemical Society Perkin Transactions, 1, 1(10): 1241-1251, (2001).
Braddock, et al., “Targeting IL-1 in Inflammatory Disease: New Opportunities for Therapeutic Intervention,” Nature Reviews Drug Discovery, 3(4): 330-340, (2004).
Brown, “Bioisosteres in Medicinal Chemistry” Published by Wiley-VCH Verlag Gmbh & Co. KGaA, Weinheim, Germany, (2012).
Bundgaard, Design of Prodrugs, Chapter 1, p. 1, 1985.
CAS 1026500-66-2; STN Entry Date: Jun. 8, 2008; CN Compound Name: 2-Thiophenesulfonamide, 5-chloro-N-[[[2-ethyl-4-[7-fluoro-6-(methylamino)-1-oxo-2(1H)-isoquinolinyl]-6-methylphenyl]amino]carbonyl]- (CA Index Name).
CAS 1026685-26-6; STN Entry Date: Jun. 9, 2008; CN Compound Name: 2-Thiophenesulfonamide, 5-chloro-N-[[[5-[6-(ethylamino)-7-fluoro-1-oxo-2(1H)-isoquinolinyl]-3-methyl-2-pyridinyl]amino]carbonyl]- (CA Index Name).
CAS 1026892-76-1; STN Entry Date: Jun. 10, 2008; CN Compound Name: Benzamide, 2,3,4,5,6-pentafluoro-N-[2-[4-[[[[(2,3,4-trifluorophenyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (CA Index Name).
CAS 1027977-57-6; STN Entry Date: Jun. 13, 2008; CN Compound Name: 2-Thiophenesulfonamide, 5-chloro-N-[4-[6-(ethylamino)-7-fluoro-1-oxo-2(1H)-isoquinolinyl]-2-(2-hydroxyethoxy)-6-methylphenyl]amino]carbonyl]- (CA Index Name).
CAS 104843-72-3 STN Entry Date:1986; CN Compound Name: 1H-Pyrazole-4-carboxylic acid, 5-[[[[(4,6-dimethyl-I-oxido-2-pyrimidinyl) amino]carbonyl]amino]sulfonyl]-1-(2-pyridinyl)-, ethyl ester (CA Index Name).
CAS 123807-74-8; STN Entry Date: 1995; CN Compound Name: 2H-1,2,5-Thiadiazino[5,6-alindole-10-sulfonamide, N-[[(3-cyano-4,6-dimethyl-2-pyridinyl)amino]carbonyl]-2-methyl-1,1-dioxide (CA Index Name).
CAS 1332606-77-5; STN Entry Date: Sep. 16, 2011; CN Compound Name: 2-(3-(3-Amino-4-(tert-butoxycarbonyl)phenylsulfonyl)ureido)-4-chlorobenzoic acid.
CAS 1347649-72-2; STN Entry Date: Dec. 2, 2001; CN Compound Name: 2-Thiophenesulfonamide, 5-chloro-N-H[4-[7-fluoro-6-(methylamino)-1-oxo-2(1H)-isoquinolinyl]-2-(methoxymethoxy)phenyl]amino]carbonyl]- (CA Index Name).
CAS 170648-58-5; STN Entry Date: 1995; CN Compound Name: Acetamide, N-[5-[[[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-y1]- (CA Index Name).
CAS 210826-40-7; STN Entry Date: Sep. 3, 1998; CN Compound Name: 2-Furansulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)- (CA Index Name).
CAS 36628-63-4; STN Entry Date: 1972; CN Compound Name: Benzamide, N-[2-[5-[[[(bicyclo[2 .2]oct-5-en-2-ylamino)carbonyl]amino]sulfonyl]-2-thienyl]ethyl]-5-chloro-2-methoxy- (CA Index Name).
CAS 438013-57-1; STN Entry Date: Jul. 10, 2002; CN Compound Name: 2-Thiophenesulfonamide, 5-methyl-N-[(1-naphthalenylamino)carbonyl]- (CA Index Name).
CAS 663215-37-0; STN Entry Date: Mar. 15, 2004; CN Compound Name: 1H-1,2,4-Triazole-1-carboxamide, N-(2-chlorophenyl)-5-[[[[(2-chlorophenyl)amino]carbonyl]amino]sulfonyl]- (CA Index Name).
CAS 84884-90-2; STN Entry Date: 1983; CN Compound Name: Acetamide, N-15-[[[[(2-methy1phenyl)amino)thioxomethyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]- (CA Index Name).
CAS 907958-32-1; STN Entry Date: Sep. 20, 2006; CN Compound Name: Acetamide, N-[5-[[[[(2,5-dioxo-4-imidazolidinyl)amino]carbonyl]amino]sulfonyl]-4-methyl-2-thiazolyl]- (CA Index Name).
CAS 959378-15-5; STN Entry Date: Dec. 21, 2007; CN Compound Name: Benzo[b]thiophene-3-carboxylic acid,4,5,6,7-tetrahydro-6,6-dimethyl-2-[[[[(2-methyl-1H-imidazol-1-yl)sulfonyl]amino]carbonyl]amino]-, ethyl ester (CA Index Name).
CAS 959664-76-7; STN Entry Date: Dec. 28, 2007; CN Compound Name: Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-6,6-dimethyl-2-[[[[(5-methyl-1H-pyrazol-1-yl)sulfonyl]amino]carbonyl]amino]-, ethyl ester (CA Index Name).
CAS RN 1026469-15-7; STN Entry Date: Jun. 8, 2008; CN Compound Name: 2-Thiophenesulfonamide, 5-chloro-N-[[[2-(cyclopropyloxy)-4-[7-fluoro-6-(methylamino)-1-oxo-2(1H)-isoquinolinyl]phenyl]amino]carbonyl]- (CA Index Name).
CAS RN 84884-72-0; STN Entry Date: 1983; CN Compound Name: Acetamide, N-[5-[[[[(2-chlorophenyl)amino]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]- (CA Index Name).
CAS RN 84884-75-3; STN Entry Date:1983; CN Compound Name: Acetamide, N-(5-[[[[(2-bromophenyl)amino]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]- (CA Index Name).
CAS RN 84884-76-4; STN Entry Date: 1983; CN Compound Name: Acetamide, N-[5-[[[[(2-methylphenyl)amino]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]- (CA Index Name).
CAS RN 84884-82-2; STN Entry Date: 1983; CN Compound Name: Acetamide, N-[5-[[[1-naphthalenylamino)carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]- (CA Index Name).
Coll, et al., “A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases,” Nature Medicine, 21(3): 248-255, (2015).
Coll, et al., “Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes,” PloS One, vol. 6, Issue 12, e29539, (Feb. 27, 2013).
Coll, et al., “Supporting Information: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes,” PloS One, vol. 6, Issue 12, e29539, (Feb. 27, 2013).
Coll, et al., “The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes,” PloS One, vol. 6, Issue 12, e29539, (Dec. 2011).
Coll, “In their own words . . . 2012 IEIIS Young Investigator Awardees,” Endotoxin Newsletter, vol. 19, No. 1, Editor Jerold Weiss, PhD, Dept. of Internal Medicine, University of Iowa, (Oct. 2013).
Cubrilovic, et al., “Determination of Protein-Ligand Binding Constants of a Cooperatively Regulated Tetrameric Enzyme Using Electrospray Mass Spectrometry,” ACS Chemical Biology, 9(1): 218-226, (2014).
Dalvie, et al., “Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings,” Chem. Res. Toxicol., vol. 15, No. 3, pp. 269-299 (2002).
Dempsey, et al., “Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia,” Journal of Neuroimmunology, vol. 275(1-2), p. 147, (2014).
Dias, et al., “Synthesis of new imidazo[4,5-d][1,3]diazepine derivatives from 5-amino-4-(cyanoformimidoyl)imidazoles,” Journal of Heterocyclic Chemistry, 33(3): 855-862, (1996).
Disease—Wikipedia, retrieved from the internet on Jan. 5, 2022 at: https://en.wikipedia.org/wiki/Disease.
Dorwald, “Side Reactions in Organic Synthesis, A Guide to Successful Synthesis Design,” Wiley-VCH, 11 pages, (2005).
EP 19708309.0 Commuication pursuant to Article 94(3) dated Mar. 23, 2023.
El-Telbany, et al., “Synthesis of Thiophenesulphonylureas and Thioureas Structurally Related to Certain Oral Hypoglycemic drugs. Part I,” Egypt Journal of Pharmaceutical Science, 16(4): 397-401, (1975).
Email from CAS Customer Center <help@cas.org>, Subject: RE: Case #00345503: question of indexing, 218-Sent: Oct. 9, 2020.
Ettmayer et al. “Lessons Learned from Marketed and Investigational Prodrugs.” J. Med. Chem., (2004), 47(10): 2393-2404.
Febbraio, “Role of interleukins in obesity: implications for metabolic disease,” Trends in Endocrinology and Metabolism, vol. 25, No. 6, pp. 312-319, (Jun. 2014).
Fleming, et al., “Novel axially chiral bis-arylthiourea-based organocatalysts for asymmetric Friedel-Crafts type reactions,” Tetrahedron Letters, 47(39): 7037-7042, (2006).
GB Application No. GB1713082.4 Search Report under Section 17(5) dated Apr. 30, 2018.
GB Application No. GB1721727.4 Search Report under Section 17(5) dated Sep. 17, 2018.
GB Application No. GB1721729.0 Search Report under Section 17(5) dated Aug. 30, 2018.
GB Application No. GB1721731.6 Search Report under Section 17(5) dated Sep. 3, 2018.
GB Application No. GB1721732.4 Search Report under Section 17(5) dated Sep. 3, 2018.
GB Application No. GB1721735.7 Search Report under Section 17(5) dated Aug. 30, 2018.
GB Application No. GB1721736.5 Search Report under Section 17(5) dated Aug. 30, 2018.
GB Application No. GB1803391.0 Search Report under Section 17(5) dated Oct. 16, 2018.
GB Application No. GB1803392.8 Search Report under Section 17(5) dated Oct. 16, 2018.
Gavrilov, et al., Pharmaceutical Technology, Preparation of Medicaments, Text Book, Moscow Publishing group “GEOTAR-Media”, 2010, 624, p. 20, Brief statement of relevance.
Groß, et al. “K+ Eflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria,” Immunity, 45(4):761-773, (2016).
Guidelines for Conducting Preclinical Drug Studies. Part one. M.: Grif and K, 2012, 944 p., ed. Mironova A.N, Brief statement of relevance.
Guo, et al., “Inflammasomes: mechanism of action, role in disease, and therapeutics,” Nature Medicine, vol. 21, No. 7, pp. 677-687, (Jul. 2015).
Hamarsheh, Frontiers in Immunology, 2020, 11:1444, 1-11. (Year: 2020).
Han, “Targeted Prodrug Design to Optimize Drug Delivery,” AAPS Pharmsci, 2 (1) article 6, 1-11, (2000).
Haneklaus, et al., “Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments,” Current opinion in immunology, 25, (1), pp. 40-45, (2013).
Hebeisen, et al., “Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase,” Bioorganic & Medicinal Chemistry Lettters, 21(11): 3237-3242, (2011).
Hill, et al., “Dual Action Sulfonylureas: NLRP3 Inhibition and Insulin Secretion,” 1st Queensland Annual Chemistry Symposium, Poster P20, Nov. 25, 2016 (and accompanying programme).
Hill, et al., “Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors,” Chem Med Chem, 12(17): 1449-1457, (2017).
Himiceskij, Chemical Encyclopedia, (1983), p. 130-131, Brief statement of relevance.
Holland, “Preparation of some additional sulfonylureas,” Journal of Organic Chemistry, 26(5): 1662-1665, (1961).
Hutton, et. al., “The NLRP3 inflammasome in kidney disease and autoimmunity,” Nephrology, 21(9): 736-744, (2016).
Jordan “Tamoxifen . . . ” Nature Rev. v.2, p. 205-213 (2003).
Kazuto, et al., “Design, synthesis and biological activity of novel non-peptidyl endothelin converting enzyme inhibitors, 1-phenyl-tetrazole-formazan analogues,” Bioorganic & Medicinal Chemistry Letters, 12(9): 1275-1278, (2002).
Khelili, et al., “Synthesis and vasodilator effects of 3- and 7-sulfonylurea-1,2,4-benzothiadiazin-1,1-dioxides on rat aorta,” Bioorganic & Medicinal Chemistry, 3(5): 495-503, (1995).
Khuntwal, et al., “Credential role of van der waal volumes and atomic masses in modeling Hepatitis C virus NS5B polymerase inhibition by tetrahydrobenzo-thiophenes using SVM and MLR aided QSAR studies,” Current Bioinformatics, 8(4): 465-471, (2013).
Kim, J Korean Med Sci, 28:1415-1423, 2013. (Year: 2013).
Kim, et al., “Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma,” 196(3): 283-297, (2017).
Krishnan, et al., “Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice,” British Journal of Pharmacology, 173(4): 752-765, (2016).
Laliberte, et al., “Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1B posttranslational processing,” Journal of Biological Chemistry, 278(19): 16567-16578, (2003).
Laporte, et al., “Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase,” Bioorganic & Medicinal Chemistry Letters, 16(1): 100-103, (2006).
Lerner, et al. “Mycobacterium tuberculosis replicates within necrotic human macrophages,” Journal of Cell Biology, 216(3): 583-594, (2017).
Li, et al., “Discovery of the first SecA inhibitors using structure-based virtual screening,” Biochemical and Biophysical Research Communications, 368(4): 839-845, (2008).
Luckhurst, et al., “A convenient synthesis of sulfonylureas from carboxylic acids and sulfonamides via an in situ Curtius rearrangement,” Tetrahedron Letters, 48(50): 8878-8882, (2007).
Ludwig-Portugall, et al., “An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice,” Kidney International, 90(3): 525-539, (2016).
Mashkovskiy, “Medicaments,” Moscow, “Medicine”, 1993, chapter 1, p. 8, Brief statement of relevance.
Meanwell, “Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design,” J. Med. Chem, 61, 5822-5880, (Feb. 2018).
Mokhtar, et al., “Synthesis of nitrogenous compounds. Part III,” Pakistan Journal of Scientific and Industrial Research, 34(1): pp. 9-15, (1991).
Monnerat, et al.,“Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice,” Nature Communications, 7(13344): 1-15, (2016).
Moossavi, 2018, 17:158, Molecular Cancer, 1-13. (Year: 2018).
Mortimer, Nature Immunology, 2016, vol. 17(10), 1176-1188. (Year: 2016).
Mridha, et al., “NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice,” Journal of Hepatology, 66(5): 1037-1046, (2017).
Mullen, et al., “Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease,” Arthritis Research & Therapy, 17:122, (2015).
Ouf, et al., “Sulphonyl Ureas and Thioureas of 1,3,4-Thiodiazole to be Tested as Hypoglycomic Agents,” Egyptian Journal of Pharmaceutical Sciences, 21(3-4): 189-198, (1980).
Ouf, et al., “Thiophene sulphonylureas structurally related to antidiabetic drugs,” Journal of Drug Research Egypt, 6(2): 123-129, (1974).
Pacini, et al., “2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp,” Bioorganic & Medicinal Chemistry Letters, 19(21): 6245-6249, (2009).
Parajuli, et al., “Prodrug as a novel approach of drug delivery—a review,” Journal of Drug Delivery & Therapeutics, 5(3), pp. 5-9, (2015).
Pinar, et al., “PB1-F2 Peptide Derived from Avian Influenza A Virus H7N9 Induces Inflammation via Activation of the NLRP3 Inflammasome,” Journal of Biological Chemistry, 292(3): 826-836, (2017).
Proks, et al., “Sulfonylurea stimulation of insulin secretion,” Diabetes, 51(3): S368-S376, (2002).
RU Application No. 2020110219/04(017079) Office Action and Search Report dated Feb. 15, 2022, English tranlsation of office action.
Rotroff, et al., “Predictive Endocrine Testing in the 21st Century Using in Vitro Assays of Estrogen Receptor Signaling Responses,” Environmental Science & Technology, 48(15): 8706-8716, (2014).
Salla, et al., “Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950,” ACS Medicinal Chemistry Letters, 7(12): 1034-1038, (2016).
Sarges, et al., “Sulfamylurea hypoglycemic agents. 6. High potency derivatives,” Journal of Medicinal Chemistry, 19(5): 695-709, (1976).
Sa̧czewski, et al., “Synthesis of Novel Aryl(heteroaryl)sulfonyl Ureas of Possible Biological Interest,” Molecules, 15(3): 1113-1126, (2010).
Shah, et al., “Analysis of Pfizer Compounds in EPA's ToxCast Chemicals-Assay Space,” Chemical Research in Toxicology, 2014, 27(1), 86-98: (2014).
Shah, et al., “Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays,” Toxicological Sciences, 147(2): 500-514, (2015).
Shao, Frontiers in Mol Neuroscience, 2018, 11:320, 1-10. (Year: 2018).
Silverman, Prodrugs and Drug Delivery Systems, The Organic Chemistry of Drug Design and Drug action, Chapter 8, pp. 352-400, 1992.
Sipes, et al., “Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays,” Chemical Research in Toxicology, 26(6): 878-895, (2013).
Sita, International J Mol Sci, vol. 22, 6984, 1-14, 2021. (Year: 2021).
Solvation—Wikipedia, retrieved from the internet on Jan. 5, 2022 at: https://en.wikipedia.org/wiki/Solvation.
Song, Frontiers in Immunology, 2017, 11:63, 1-17. (Year: 2017).
St Jean, et al., “Mitigating Heterocycle Metabolism in Drug Discovery,” Journal of Medicinal Chemistry, 55, pp. 6002-6020, (2012).
Stella, Valentino. “Prodrugs as therapeutics.” Expert Opin. Ther. Patents (2004), 14(3): 277-280.
Stocks, et al., “On Chemistry, on Medical Chemistry,” Published in Great Britain by Sci-Ink Limited, ISBN 978-0-9550072-3-1, pp. 214-215, (2007).
Testa, Bernard. “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68 (2004): 2097-2106.
U.S. Appl. No. 16/638,648, Final Office Action dated May 27, 2022.
U.S. Appl. No. 16/638,648, Non-Final Office Action dated Oct. 12, 2021.
U.S. Appl. No. 16/638,648, Notice of Allowance dated Oct. 18, 2022.
U.S. Appl. No. 16/638,648, Requirement for Restriction/Election dated Apr. 20, 2021.
U.S. Appl. No. 16/638,648, Supplemental Notice of Allowance dated Jan. 20, 2023.
U.S. Appl. No. 16/638,700, Final Office Action dated Mar. 20, 2023.
U.S. Appl. No. 16/638,700, Final Office Action dated May 16, 2022.
U.S. Appl. No. 16/638,700, Non-Final Office Action dated Oct. 19, 2022.
U.S. Appl. No. 16/638,700, Non-Final Office Action dated Sep. 10, 2021.
U.S. Appl. No. 16/638,700, Notice of Allowance and Interview Summary dated Sep. 29, 2023.
U.S. Appl. No. 16/638,700, Requirement for Restriction/Election dated May 3, 2021.
U.S. Appl. No. 16/638,704, Final Office Action dated Jul. 8, 2022.
U.S. Appl. No. 16/638,704, Final Office Action dated Oct. 3, 2023.
U.S. Appl. No. 16/638,704, Non-Final Office Action dated Dec. 30, 2022.
U.S. Appl. No. 16/638,704, Requirement for Restriction/Election dated Apr. 29, 2021.
U.S. Appl. No. 16/638,707, Non-Final Office Action dated Oct. 15, 2021.
U.S. Appl. No. 16/638,707, Notice of Allowance and interview Summary dated Apr. 21, 2022.
U.S. Appl. No. 16/638,707, Notice of Allowance dated Sep. 7, 2022.
U.S. Appl. No. 16/638,707, Requirement for Restriction/Election dated May 13, 2021.
U.S. Appl. No. 16/762,000, Final Office Action dated Nov. 15, 2022.
U.S. Appl. No. 16/762,000, Non-Final Office Action dated Apr. 26, 2023.
U.S. Appl. No. 16/762,000, Non-Final Office Action dated Apr. 4, 2022.
U.S. Appl. No. 16/762,000, Non-Final Office Action dated Dec. 26, 2023.
U.S. Appl. No. 16/762,000, Requirement for Restriction/Election dated Nov. 1, 2021.
U.S. Appl. No. 16/977,241, Non-Final Office Action dated Apr. 25, 2023.
U.S. Appl. No. 16/977,241, Non-Final Office Action dated Jun. 13, 2022.
U.S. Appl. No. 16/977,241, Notice of Allowance dated Jan. 6, 2023.
U.S. Appl. No. 16/977,241, Notice of Allowance dated Sep. 13, 2023.
U.S. Appl. No. 16/977,241, Requirement for Restriction/Election dated Nov. 30, 2021.
Urban, et al., “Novel Synthesis of 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an Anti-inflammatory Agent,” Synthetic Communications, 33(12): 2029-2043, (2003).
WIPO Application No. PCT/EP2018/072111, PCT International Preliminary Report on Patentability dated Feb. 27, 2020.
WIPO Application No. PCT/EP2018/072111, PCT International Search Report and Written Opinion of the International Searching Authority dated Nov. 6, 2018.
WIPO Application No. PCT/EP2018/072115, PCT International Preliminary Report on Patentability dated Feb. 27, 2020.
WIPO Application No. PCT/EP2018/072115, PCT International Search Report and Written Opinion of the International Searching Authority dated Oct. 24, 2018.
WIPO Application No. PCT/EP2018/072119, PCT International Preliminary Report on Patentability dated Feb. 27, 2020.
WIPO Application No. PCT/EP2018/072119, PCT International Search Report and Written Opinion of the International Searching Authority dated Dec. 11, 2018.
WIPO Application No. PCT/EP2018/072123, PCT International Preliminary Report on Patentability dated Feb. 27, 2020.
WIPO Application No. PCT/EP2018/072123, PCT International Search Report and Written Opinion of the International Searching Authority dated Nov. 14, 2018.
WIPO Application No. PCT/EP2018/072125, PCT International Preliminary Report on Patentability dated Feb. 27, 2020.
WIPO Application No. PCT/EP2018/072125, PCT International Search Report and Written Opinion of the International Searching Authority dated Oct. 22, 2018.
WIPO Application No. PCT/EP2018/080737, PCT International Preliminary Report on Patentability dated May 22, 2020.
WIPO Application No. PCT/EP2018/080737, PCT International Search Report and Written Opinion of the International Searching Authority dated Jan. 30, 2019.
WIPO Application No. PCT/EP2018/080739, PCT International Preliminary Report on Patentability dated May 22, 2020.
WIPO Application No. PCT/EP2018/080739, PCT International Search Report and Written Opinion of the International Searching Authority dated Jan. 25, 2019.
WIPO Application No. PCT/EP2018/080746, PCT International Preliminary Report on Patentability dated May 22, 2020.
WIPO Application No. PCT/EP2018/080746, PCT International Search Report and Written Opinion of the International Searching Authority dated Jan. 25, 2019.
WIPO Application No. PCT/EP2019/055127, PCT International Preliminary Report on Patentability dated Sep. 17, 2020.
WIPO Application No. PCT/EP2019/055127, PCT International Search Report and Written Opinion of the International Searching Authority dated Apr. 24, 2019.
WIPO Application No. PCT/IB2017/053059, PCT International Preliminary Report on Patentability dated Dec. 5, 2019.
WIPO Application No. PCT/IB2017/053059, PCT International Search Report and Written Opinion of the International Searching Authority dated Aug. 8, 2017.
Wambaugh, et al., “High-Throughput Models for Exposure-Based Chemical Prioritization in the ExpoCast Project,” Environmental Science & Technology, 47(15): 8479-8488, (2013).
Waterman, et al. “Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms,” Pharmaceutical Research, 24(4): 780-790, (2007).
Youssef, et al., “N1, N3-Diaryl sulfonylureas as possible anticancer agents,” Alexandria Journal of Pharmaceutical Sciences, 8(3): 223-225, (1994).
Youssef, et al., “Synthesis of sulofenur analogues as antitumour agents: part II,” Medicinal Chemistry Research, 11(9): 481-503, (2002).
Zawilska, et al., “Prodrugs: a challenge for the drug development,” Pharmacological reports: PR, vol. 65, No. 1, pp. 1-14, (Apr. 2013).
Zhao, 2020, Frontiers in Immunology, 11:211, 1-8. (Year: 2020).
Zhen, et al., “Recent advances in discovery and development of promising therapeutics against Hepatitis C virus NS5B RNA-dependent RNA polymerase,” Mini Reviews in Medicinal Chemistry, 5(12): 1103-1112, (2005).
Zhulenko, et al., “Pharmacology”, Moscow: KolosS, p. 34-35, (2008), Brief statement of relevance.